Investigating how psychedelics such as psilocybin act on serotonin receptors, researchers shed new light on how the drugs affect consciousness and assist in treating a range of mental health disorders.
Researchers shed light on how different SSRI antidepressants may work to help fight symptoms of depression in the brain.
Study identifies potential new drugs that can help treat depression and anxiety disorders without many of the adverse effects of other medications currently under evaluation.
Used to help treat mental health conditions, and improve spirituality, the plant-based psychoactive ayahuasca is becoming more popular. Researchers say there is a high rate of adverse physical and psychological effects from using ayahuasca although they are not generally severe.
Lisdexamfetamine (Vyvanse), a medication commonly used to treat ADHD, lowers the risk of hospitalization and death for those with amphetamine use disorder.
Those with PTSD are almost twice as likely to develop alcohol use disorder than their peers who have not experienced trauma. Researchers report drugs that block FKBP5, such as benztropine, a drug used to control symptoms of Parkinson's disease, and the experimental compound SAFit2 reduce alcohol preference and drinking in models of PTSD.
Ketamine alters neural activity in the cerebral cortex, silencing normally active neurons and activating neurons that are normally inactive. The ketamine activity-induced "switch" in brain regions associated with depression may help explain its treatment effects.
Study reveals how methylphenidate interacts with cognitive control networks and attention behaviors. Methylphenidate changes spontaneous neural activity in reward and cognitive control systems in children with ADHD. The changes result in more stable sustained attention.
A single psychedelic experience increases beliefs about consciousness, meaning, purpose, and a range of nonphysicalist beliefs.
The common antidepressant Prozac (fluoxetine) provokes an inflammatory response in the amniotic sac. The findings may reveal the underlying factor of why women who take SSRI antidepressants are at higher risk of preterm birth.
Researchers identified 20 drug candidates that reduce C4 immune protein secretion from astrocytes. The discovery could pave the way to treating schizophrenia and other disorders associated with C4 dysregulation in astrocytes.